Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: Implications for clinical photodynamic therapy

Free Radical Biology and Medicine

Volumn 28, Issue 4, 2000, Pages 537-548

  Fuchs, Jürgen ^a   Weber, Stefan ^b   Kaufmann, Roland ^a,c  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (Germany)

Author keywords

Aminolevulinic acid; Cancer; Free radicals; Genotoxicity; Mutagenicity; Photodynamic therapy; Porphyrins; Protoporphyrin; Reactive oxygen species; Singlet oxygen

Indexed keywords

AMINOLEVULINIC ACID; METHOXSALEN; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; PORPHYRIN; PROTOPORPHYRIN; REACTIVE OXYGEN METABOLITE; UROPORPHYRIN;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CARCINOGENESIS; GENE EXPRESSION; GENOTOXICITY; HUMAN; MOUSE; MUTAGENICITY; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; SKIN CANCER; ULTRAVIOLET RADIATION;

AMINOLEVULINIC ACID; ANIMALS; CARCINOGENS; HUMANS; MICE; MUTAGENS; NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS;

ANIMALIA;

EID: 0034652554     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(99)00255-5     Document Type: Review

References (176)

1. Dougherty T.J., Kaufman J.E., Goldfarb A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 38:1978;2628-2636.
2. Fisher A.M.R., Murphree A.L., Gomer C.J. Clinical and preclinical photodynamic therapy. Laser Surg. Med. 17:1995;2-31.
3. Boyle R.W., Dolphin D. Structure and biodistribution relationships of photodynamic sensitizers. Photochem. Photobiol. 64:1996;469-485.
4. Szeimies R.M., Calzavara-Pinton P., Karrer S., Ortel B., Landthaler M. Topical photodynamic therapy in dermatology. J. Photochem. Photobiol. B Biol. 36:1996;213-219.
5. Fritsch C., Goerz G., Ruzicka T. Photodynamic therapy in dermatology. Arch. Dermatol. 134:1998;207-214.
6. Malik Z., Lugachi H. Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins. Br. J. Cancer. 56:1987;589-595.
7. Kennedy J.C., Pottier R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J. Photochem. Photobiol. B Biol. 14:1992;275-292.
8. Kennedy J.C., Pottier R.H., Pross D.C. Photodynamic therapy with endogenous protoporphyrin IX. Basic principles and present clinical experience. J. Photochem. Photobiol. B Biol. 6:1990;143-148.
9. Dietel W., Bolsen K., Dickson E., Fritsch C., Pottier R., Wendenburg R. Formation of water-soluble porphyrins and protoporphyrin IX in 5-aminolevulinic-acid-incubated carcinoma cells. J. Photochem. Photobiol. B Biol. 33:1996;225-231.
10. Dietel, W.; Fritsch, C.; Pottier, R. H.; Wendenburg, R. 5-aminolaevulinic-acid-induced formation of different porphyrins and their photomodifications. Lasers Med. Sci 12: 226-236; 1997.
11. Tabata K., Ogura S.I., Okura I. Photodynamic efficiency of protoporphyrin IX comparison of endogenous protoporphyrin IX induced by 5-aminolevulinic acid and exogenous porphyrin IX. Photochem. Photobiol. 66:1997;842-846.
12. Gaullier J.M., Geze M., Santus R., Sa E., Melo T.S., Maziere J.C., Bazin M., Morliere P., Dubertret L. Subcellular localization and photosensitization by protoporphyrin IX in human keratinocytes and fibroblasts cultivated with 5-aminolevulinic acid. Photochem. Photobiol. 62:1995;114-122.
13. Ghiggino K.P., Bennet L.E., Henderson R.W. Photochemical properties of porphyrin an agent for use in tumor phototherapy. Photochem. Photobiol. 47:1988;65-72.
14. Grossweiner L.I., Blum A., Goyal G.C. Photophysics and photochemistry of hematoporphyrin, hematoporphyrin derivative and uroporphyrin I. Adv. Exp. Med. Biol. 193:1985;181-192.
15. Diwu Z., Lown J.W. Phototherapeutic potential of alternative photosensitizers to porphyrins. Pharmacol. Ther. 63:1994;1-35.
16. Henderson B.W., Dougherty T.J. How does photodynamic therapy work? Photochem. Photobiol. 55:1992;145-157.
17. Gorman A.A., Rodgers M.A.J. Current perspectives of singlet oxygen detection in biological environments. J. Photochem. Photobiol. B Biol. 14:1992;159-176.
18. Fernandez J.M., Bilgin M.D., Grossweiner L.I. Singlet oxygen generation by photodynamic agents. J. Photochem. Photobiol. B Biol. 37:1997;131-140.
19. Kreitner M., Ebermann R., Alth G. Quantitative determination of singlet oxygen. Production by porphyrins. J. Photochem. Photobiol. B Biol. 36:1996;109-111.
20. Jones L.R., Grossweiner L.I. Singlet oxygen generation by Photofrin in homogeneous and light-scattering media. J. Photochem. Photobiol. B Biol. 26:1994;249-256.
21. Weishaupt K.R., Gomer C.J., Dougherty T.J. Identification of singlet oxygen as the cytotoxic agent in photo-inactivation of a murine tumor. Cancer Res. 36:1976;2326-2329.
22. Athar M., Mukhtar H., Bickers D.R. Differential role of reactive oxygen intermediates in photofrin-I-mediated and photofrin-II-mediated photoenhancement of lipid peroxidation in epidermal microsomal membranes. J. Invest. Dermatol. 90:1988;652-657.
23. Van Lier, J. A. Phthalocyanines as sensitizers for PDT of cancer. In: Kessel, D., ed. Photodynamic Therapy of Neoplastic Disease, Vol.1. Boca Raton, FL: CRC Press; 1990:279-291.
24. Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J. Photochem. Photobiol. B Biol. 39:1997;1-18.
25. Del C., Battle A.M. Porphyrins, porphyrias, cancer and photodynamic therapya model for carcinogenesis. J. Photochem. Photobiol. B Biol. 20:1993;5-22.
26. Moan J. The photochemical yield of singlet oxygen from porphyrins in different states of aggregation. Photochem. Photobiol. 39:1984;445-449.
27. Pathak, M. A.; Carraro, C. Reactive oxygen species in cutaneous photosensitivity reactions in porphyrias and PUVA photochemotherapy and in melanin pigmentation. In: Hayaishi, O.; Imamura, S.; Miyachi, Y., eds. The Biological Role of Reactive Oxygen Species in Skin. New York: Elsevier 1987:75-94.
28. Buettner G., Need M. Hydrogen peroxide and hydroxyl free radical production by hematoporphyrin derivative, ascorbate and light. Cancer Lett. 25:1985;297-304.
29. Douki T., Onuki J., Medeiros M.H.G., Bechara E.J.H., Cadet J., Di Mascio P. Hydroxyl radicals are involved in the oxidation of isolated and cellular DNA bases by 5-aminolevulinic acid. FEBS Lett. 428:1998;93-96.
30. Haberman, H. F.; Menon, I. A. Mechanism of photosensitivity due to porphyrins: Chemical species involved and relevance to clinical porphyrias. In: Fuchs, J.; Packer, L., eds. Oxidative Stress in Dermatology. New York: Marcel Dekker Inc. 1993:361-374.
31. Jori G., Galiazzo G., Scoffone E. Photodynamic action of porphyrins on aminoacids and proteins. I. Selective photooxidation of methionine in aqueous solution. Biochemistry. 8:1969;2868-2875.
32. Menon I.A., Becker M.A.C., Persad S.D., Haberman H.F. Quantitation of hydrogen peroxide formed during UV-visible irradiation of protoporphyrin, coproporphyrin and uroporphyrin. Clin. Chim. Acta. 186:1990;375-382.
33. Aveline B., Hasan T., Redmond R. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem. Photobiol. 59:1994;328-335.
34. -2) generated by irradiation of benzoporphyrin derivative monoacid ring A. Photochem. Photobiol. 65:1997;818-827.
35. Zaidi S.I., Agarwal R., Eichler G., Richter B.D., Kenney M.E., Mukhtar H. Photodynamic effects of new silicon phthalocyanines in-vitro studies utilizing rat hepatic microsomes and human erythrocyte ghosts as model membrane sources. Photochem. Photobiol. 58:1993;204-210.
36. Daziano J.P., Steenken S., Chabannon C., Mannoni P., Chanon M., Julliard M. Photophysical and redox properties of a series of phthalocyanines relation with their photodynamic activities of TF-1 and Daudi leukemic cells. Photochem. Photobiol. 64:1996;712-719.
37. He, J.; Larkin, H. E., Li, Y. S.; Rihter, B. D.; Zaidi, S. I. A.; Rodgers, M. A. J.; Mukhtar, H.; Kenney, M. E.; Oleinick, N. L. The synthesis, photophysical and photobiological properties and in vitro structure activity relationsships of a set of silicon phthalocyanine PDT photosensitizers. Photochem. Photobiol. 65:581-586; 1997.
38. Mori K., Ohta M., Sano A., Yoneya S., Sonoda M., Kaneda A., Sato Y. Potential of photodynamic therapy with a second generation sensitizer mono-L-aspartyl chlorin e6. Nippon Ganka Gakkai Zasshi. 101:1997;134-140.
39. Decreau R., Viola A., Hadjur C., Richard M.J., Jeunet A., Favier A., Julliard M. Dynamic phototherapy study of anti-tumor potentials of bis(tri-n-hexylsiloxy) silicon phthalocyanine on malignant achromic M6 melanocytes. EPR study of phototoxic mechanism. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. 191:1997;639-657.
40. . by irradiation of the photosensitizer zinc(II)phthalocyanine. J Photochem Photobiol. B Biol. 38:1997;196-202.
41. Aveline B.M., Sattler R.M., Redmond R.W. Environmental effects on cellular photosensization correlation of phototoxicity mechanism with transient absorption spectroscopy measurements. Photochem. Photobiol. 68:1998;51-62.
42. Nitzan Y., Wexler H.M., Finegold S.M. Inactivation of anaerobic bacteria by various photosensitized porphyrins or by hemin. Curr. Microbiol. 29:1994;125-131.
43. Monteiro H.P., Abdalla D.S.P., Augusto O., Bechara E.J.H. Free radical generation during delta-aminolevulinic acid autoxidation induction by hemoglobin and connections with porphyrinpathies. Arch. Biochem. Biophys. 271:1989;206-216.
44. Demasi M., Costa C.A., Pascual C., Llesuy S., Bechara E.J.H. Oxidative tissue response promoted by 5-aminolevulinic acid promptly induces the increase of plasma antioxidant capacity. Free Radic. Res. 26:1997;235-243.
45. Braverman S., Helson C., Helson L. Hemin toxicity in a human epitheloid sarcoma cell line. Anti Cancer Res. 15:1995;1963-1967.
46. Costa C.A., Trivelato G.C., Pinto A.M.P., Bechara E.J.H. Correlation between plasma 5-aminolevulinic acid concentrations and indicators of oxidative stress in lead-exposed workers. Clin. Chem. 43:1997;1196-1202.
47. Fraga C.G., Onuki J., Lucesoli F., Bechara E.J., di Mascio P. 5-aminolevulinic acid mediates in vivo and in vitro formation of 8-hydroxy-2'-deoxyguanosine in DNA. Carcinogenesis. 15:1994;2241-2244.
48. Ortel B., Tanew A., Hönigsmann H. Lethal photosensitization by endogenous porphyrins of PAM cellsmodification by desforrioxamine. J Photochem. Photobiol. B Biol. 17:1993;273-278.
49. Schoenfeld N., Mamet R., Nordenberg Y., Shafran M., Babuskin T., Malik Z. Protoporphyrin biosynthesis in melanoma B16 cells stimulated by 5-aminolevulinic acid and chemical inducers characterization of photodynamic inactivation. Int. J. Cancer. 56:1994;106-112.
50. Princ F.G., Juknat A.A., Amitrano A.A., Batlle A. Effect of reactive oxygen species promoted by delta-aminolevulinic acid on porphyrin biosynthesis and glucose uptake in rat cerebellum. Gen. Pharmacol. 31:1998;143-148.
51. Demasi M., Penatti C.A.A., Delucia R., Bechara E.J.H. The prooxidant effect of 5-aminolevulinic acid in the brain tissue of rats implications in neuropsychiatric manifestations in porphyrias. Free Radic. Biol. Med. 20:1996;291-299.
52. Carneiro R.C.G., Reiter R.J. Delta-Aminolevulinic acid-induced lipid peroxidation in rat kidney and liver is attenuated by melatonin an in vitro and in vivo study. J. Pineal. Res. 24:1998;131-136.
53. Neal R., Yang P., Fiechtl J., Yildiz D., Gurer H., Ercal N. Pro-oxidant effects of delta-aminolevulinic acid (delta-ALA) on Chinese hamster ovary (CHO) cells. Toxicol. Lett. 91:1997;169-178.
54. Monteiro H.P., Stern A. Redox modulation of tyrosin phosphorylation dependent signal transduction pathways. Free Radic. Biol. Med. 21:1996;323-333.
55. Sun Y., Oberley L.W. Redox regulation of transcriptional activators. Free Radic. Biol. Med. 21:1996;335-348.
56. Flohe L., Brigelius-Flohe R., Saliou C., Traber M.G., Packer L. Redox regulation of NF-kappa B activation. Free Radic. Biol. Med. 22:1997;1115-1126.
57. Sen C.K., Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 10:1996;709-720.
58. Grether-Beck S., Olaizola-Horn S., Schmitt H., Grewe M., Jahnke A., Johnson J.P., Briviba K., Sies H., Krutmann J. Activation of transcription factor AP-2 mediates UVA radiation- and singlet oxygen-induced expression of the human intercellular adhesion molecule 1 gene. Proc. Natl. Acad. Sci. USA. 93:1996;14586-14591.
59. Tao J., Sanghera J.S., Pelech S.L., Wong G., Levy J.G. Stimulation of stress-activated protein kinase and p38 HOG1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative. J. Biol. Chem. 271:1996;27107-27115.
60. Klotz L.O., Briviba K., Sies H. Singlet oxygen mediates the activation of JNK by UVA radiation in human skin fibroblasts. FEBS Lett. 408:1997;289-291.
61. Keyse S.M. An emerging family of dual specificity MAP-kinase phosphatases. Biochim. Biophys. Acta. 1265:1995;152-160.
62. Scharffetter-Kochanek K., Wlaschek M., Brenneisen P., Schauen M., Blaudschun R., Wenk J. UV-induced reactive oxygen species in photocarcinogenesis and photoaging. Biol. Chem. 378:1997;1247-1257.
63. Ryter S.W., Tyrrell R.M. Singlet molecular oxygen (1O-2) A possible effector of eukaryotic gene expression. Free Radic. Biol. Med. 24:1998;1520-1534.
64. Briviba K., Klotz L.O., Sies H. Toxic and signaling effects of photochemically or chemically generated singlet oxygen in biological systems. Biol. Chem. 378:1997;1259-1265.
65. Luna M.C., Wong S., Gomer C.J. Photodynamic therapy mediated induction of early response genes. Cancer Res. 54:1994;1374-1380.
66. Kick G., Messer G., Plewig G., Kind P., Goetz A.E. Strong and prolonged induction of c-jun and c-fos proto-oncogenes by photodynamic therapy. Br. J. Cancer. 74:1996;30-36.
67. Rüther U., Komitowski D., Schubert F.R., Wagner E.F. C-fos expression induces bone tumors in transgenic mice. Oncogene. 4:1989;861-865.
68. Haas S., Kaina B. c-fos is involved in the cellular defence against the genotoxic effect of UV radiation. Carcinogenesis. 16:1995;985-991.
69. Klotz L.O., Briviba K., Fritsch C., Tsacmacidis N., Schliess F., Ruzicka T., Sies H. Activation of JNK and P38 but not ERK MAP Kinases in human skin cells by 5-aminolevulinate PDT, UVA and singlet oxygen. J. Invest. Dermatol. 110:1998;624.
70. Agarwal M.L., Clay M.E., Harvey E.J., Evans H., Antunez A.R., Oleinick N.L. Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res. 51:1991;5993-5996.
71. Zaidi S.L., Oleinick N.L., Zaim M.T., Mukhtar H. Apoptosis during photodynamic therapy induced ablation of RIF-1 tumors in C3H mice electron microscopic, histopathologic and biochemical evidence. Photochem. Photobiol. 58:1993;771-776.
72. He X.Y., Sikes R., Thomson S., Chung L.W.K., Jacques S.L. Photodynamic therapy with photofrin II induces programmed cell death in carcinoma cell lines. Photochem. Photobiol. 59:1994;468-473.
73. Colussi V.C., Feyes D.K., Mulvihill J.W., Li Y.S., Kenney M.E., Elmets C.A., Oleinick N.L., Mukhtar H. Phthalocyanine 4 (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts. Photochem. Photobiol. 69:1999;236-241.
74. Luo Y., Chang C.K., Kessel D. Rapid initiation of apoptosis by photodynamic therapy. Photochem. Photobiol. 63:1996;528-534.
75. Luo Y., Kessel D. Initiation of apoptosis versus necrosis by photodynamic therapy with chloroaluminum phthalocyanine. Photochem. Photobiol. 66:1997;479-483.
76. Noodt B.B., Berg K., Stokke T., Peng Q., Nesland J.M. Apoptosis and necrosis induced with light and 5-aminolevulinic acid-derived protoporphyrin IX. Br. J. Cancer. 74:1996;22-29.
77. Oleinick N.L., Agarwal M.L., Berger N.A., Berger S., Cheng M.F., Chatterjee S., He J., Kenney M.E., Larkin H.E., Mukhtar H., Rihter B.D., Zaida S.I.A. Signal transduction and metabolic changes during tumor cell apoptosis following phthalocyanine sensitized photodynamic therapy. Sic. Photo. Optical Instrum. Engin. 1881:1993;252-261.
78. Ketabchi A., Macrobert A., Speight P.M., Bennett J.H. Induction of apoptotic cell death by photodynamic therapy in human keratinocytes. Arch. Oral Biol. 43:1998;143-149.
79. Granville D.J., Jiang H., An M.T., Levy J.G., McManus B.M., Hunt D.W. Bcl-2 overexpression blocks caspase activation and downstream apoptotic events instigated by photodynamic therapy. Br. J. Cancer. 79:1999;95-100.
80. Ahmad N., Feyse D.K., Agarwal R., Mukhtar H. Photodynamic therapy results in induction of WAF1/CIP1/P21 leading to cell cycle arrest and apoptosis. Proc. Natl. Acad. Sci. USA. 95:1998;6977-6982.
81. Verwanger T., Schnitzhofer G., Krammer B. Expression kinetics of the (proto) oncogenes c-myc and blc-2 following photodynamic treatment of normal and transformed human fibroblasts with 5-aminolaevulinic acid-stimulated endogenous protoporphyrin IX. J. Photochem. Photobiol. B Biol. 45:1998;131-135.
82. Schreck R., Rieber P., Baeuerle P.A. Reactive oxygen intermediates as apparently widely used second messengers in the activation of the NFκB transcription factor and HIV-1. Eur. Mol. Biol. Organ. J. 10:1991;2247-2258.
83. Anderson M.T., Staal F.J., Gitler C., Herzenberg L.A., Herzenberg L.A. Separation of oxidant-initiated and redox regulated steps in the NF-kappa B signal transduction pathway. Proc. Natl. Acad. Sci. USA. 91:1994;11527-11531.
84. Kick G., Messer G., Goetz A., Plewig G., Kind P. Photodynamic therapy induces expression of interleukin 6 by activation of AP-1 but not NF-kappa B DNA binding. Cancer Res. 55:1995;2373-2379.
85. Ryter S.W., Gomer C.J. Nuclear factor KAPPA-B binding activity in mouse L1210 cells following photofrin II-mediated photosensitization. Photochem. Photobiol. 58:1993;753-756.
86. Matroule J.Y., Bonizzi G., Morliere P., Paillous N., Santus R., Bours V., Piette J. Pyropheophorbidea methyl estermediated photosensitization activates transcription factor NF-κB through the interleukin-1 receptor signaling pathway. J. Biol. Chem. 274:1999;2988-3000.
87. Evans S., Matthews W., Perry R., Fraker D., Norton J., Pass H.I. Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J. Natl. Cancer Inst. 82:1990;34-39.
88. Herrmann G., Wlaschek M., Bolsen K., Prenzel K., Goerz G., Scharffetter-Kochanek K. Photosensitization of uroporphyrin augments the ultraviolet A-induced synthesis of matrix metalloproteinases in human dermal fibroblasts. J. Invest. Dermatol. 107:1996;398-403.
89. Glinski J.A., David E., Warren T.C., Hansen G., Leonard S.F., Pitner P., Pav S., Arvigo R., Balick M.J., Panti E. Inactivation of cell surface recptors by pheophorbide a, a green pigment isolated from Psychotri acuminata. Photochem. Photobiol. 62:1995;144-150.
90. Simkin G.O., King D.E., Levy J.G., Chan A.H., Hunt D.W.C. Inhibition of contact hypersensitivity with different analogs of benzoporphyrin derivative. Immunopharmacol. 37:1997;221-230.
91. Curry P., Levy J. Stress protein expression in murine tumor cells following photodynamic therapy with benzoporphyrin derivative. Photochem. Photobiol. 58:1993;374-378.
92. Gomer C.J., Rucker N., Ferrario A., Wong S. Properties and applications of photodynamic therapy. Radiat. Res. 120:1989;1-18.
93. Gomer C.J., Ryter S.W., Ferrario A., Rucker N., Wong S., Fischer A.M.R. Photodynamic therapy mediated oxidative stress can induce expressions of heat shock proteins. Cancer Res. 56:1996;2355-2360.
94. Gomer C.J., Luna M., Ferrario A., Rucker N. Increased transcription and translation of heme oxygenase in Chinese hamster fibroblasts following photodynamic stress or photofrin II incubation. Photochem. Photobiol. 53:1991;275-279.
95. Bressoud D., Jomini V., Tyrrell R.M. Dark induction of haem oxygenase messenger mRNA by haematoporphyrin derivative and zinc phthalocyanine; agents for photodynamic therapy. J. Photochem. Photobiol. B Biol. 14:1992;311-318.
96. Troll W., Wiesner R. The role of oxygen radicals as a possible mechanism of tumor promotion. Ann. Rev. Pharmacol. Toxicol. 25:1985;509-528.
97. Kensler T., Guyton K., Egner P., McCarthy T., Lesko S., Akman S. Role of reactive intermediates in tumor promotion and progression. Prog. Clin. Biol. Res. 391:1995;103-116.
98. Pryor W.A. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ. Health Perspec. 105:(Suppl 4):1997;875-882.
99. Epe B. Genotoxicity of singlet oxygen. Chem. Biol. Interact. 80:1991;239-260.
100. Ribeiro D.T., Madzak C., Sarasin A., Di Mascio P., Sies H., Menck C.F.M. Singlet oxygen induced DNA damage and mutagenicity in a single-stranded SV40-based shuttle vector. Photochem. Photobiol. 55:1992;39-46.
101. Floyd R.A., West M.S., Eneff K.L., Schneider J.E. Methylene blue plus light mediates 8-hydroxyguanosine formation in DNA. Arch. Biochem. Biophys. 273:1989;106-111.
102. Devasagayam T.P.A., Steenken S., Obendorf M.S.W., Schulz W.A., Sies H. Formation of 8-hydroxydeoxyguanosine and generation of strand breaks at guanine residues in DNA by singlet oxygen. Biochemistry. 30:1991;6283-6289.
103. Sies H., Menck C.F.M. Singlet oxygen induced DNA damage. Mutat. Res. 275:1992;367-375.
104. Retel J., Hoebbe B., Braun J.E.F., Lutgerink J.T., van den Akker E., Wanamarta A.H., Joenje H., Lafleur M.V.M. Mutational specificity of oxidative DNA damage. Mutat. Res. 299:1993;165-182.
105. Van den Akker E., Lutgerink J.T., Lafleur M.V.M., Joenje H., Retel J. The formation of one-G deletions as a consequence of singlet oxygen induced DNA damage. Mutat. Res. 309:1994;45-52.
106. Sera N., Tokiwa H., Miyata N. Mutagenicity of the fullerene C-60-generated singlet oxygen dependent formation of lipid peroxides. Carcinogenesis. 17:1996;2163-2169.
107. Fiedler D.M., Eckl P.M., Krammer B. Does d-aminolaevulinic acid induce genotoxic effects? J. Photochem. Photobiol. B Biol. 33:1996;39-44.
108. Hiraku Y., Kawanishi S. Mechanism of oxidative DNA damage induced by delta-aminolevulinic acid in the presence of copper ion. Cancer Res. 56:1996;1786-1793.
109. Oteiza, P. I.; Kleinman, C. G.; Demasi, M.; Bechara, E. J. H. 5-Aminolevulinic acid induces iron release from ferritin. Arch. Biochem. Biophys. 316:607-611; 1995.
110. Onuki, J.; Medeiros, M. H. G.; Bechara, E. J. H.; Di Mascio P. 5-Aminolevulinic acid induces single-strand breaks in plasmid pBR322 DNA in the presence of Fe-2+ ions. Biochim. Biophys. Acta. 1225:259-263; 1994.
111. Douki, T.; Onuki, J.; Medeiros, M. H. G.; Bechara, E. J. H.; Cadet, J.; Di Mascio P. DNA alkylation by 4,5-dioxovaleric acid, the final oxidation product of 5-aminolevulinic acid. Chem. Res. Toxicol. 11:150-157; 1998.
112. Fiedler D.M., Krammer B., Eckl P.M. Cyto- and genototoxic potentials of the photosensitizer Photosan 3 in the absence of light. J. Photochem. Photobiol. B Biol. 22:1994;241-246.
113. Schuitmaker J.J., Vogel E.W., Nagelkerke J.F., Bos R.P. Mutagenicity and dark toxicity of the second generation photosensitizer bacteriochlorin a. J. Photochem. Photobiol. B Biol. 47:1998;211-215.
114. Noodt B.B., Kvam E., Steen H.B., Moan J. Primary DNA damage.; HPRT mutation and cell inactivation photo-induced with various sensitizers in V79 cells. Photochem. Photobiol. 58:1993;541-547.
115. Noodt B.B., Moan J., Kvan E., Steen H.B. No correlation between DNA strand breaks and HPRT mutation induced by photochemical treatment in V79 cells. Mutat. Res. 323:1994;75-79.
116. Oleinick N.L., Evans H.H. The photobiology of photodynamic therapy cellular targets and mechanisms. Radiat. Res. 150:(Suppl):1998;S146-S156.
117. Evensen F., Moan J. Photodynamic action and chromosomal damage a comparison of haematoporphyrin derivative (HpD) and light with X-irradiation. Br. J. Cancer. 45:1982;456-465.
118. Ben-Hur E., Fujihara F., Suzuki F., Elkind M.M. Genetic toxicology of the photosensitization of Chinese hamster cells by phthalocyanines. Photochem. Photobiol. 45:1987;227-230.
119. Moan J., Waksvik H., Christensen T. DNA single stranded breaks and sister chromatid exchanges induced by treatment with hematoporphyrin and light or by X-rays in human NHIK 3025 cells. Cancer Res. 40:1980;2915-2918.
120. Ramakrishnan N., Oleinick N.L., Clay M.E., Horng M.F., Antunez A.R., Evans H.H. DNA lesions and DNA degradation in mouse lymphoma L5178Y cells after photodynamic treatment sensitized by chloroaluminium phthalocyanine. Photochem. Photobiol. 50:1989;373-378.
121. Gomer C.J., Rucker N.L., Banerjee A., Benedict W.F. Comparison of mutagenicity and induction of sister chromatid exchange in Chinese hamster cells exposed to hematoporphyrin derivative photoradiation.; ionizing radiation, or ultraviolet radiation. Cancer Res. 43:1983;2622-2627.
122. Evans H.H., Horng M.F., Ricanati M., Deahl J.T., Oleinick N.L. Mutagenicity of photodynamic therapy as compared to UVC and ionizing radiation in human and murine lymphoblast cell lines. Photochem. Photobiol. 66:1997;690-696.
123. Pflaum M., Kielbassa C., Garmyn M., Epe B. Oxidative DNA damage induced by visible light in mammalian cells Extent, inhibition by antioxidants and genotoxic effects. Mutat. Res. 408:1998;137-146.
124. Giri U., Sharma S.D., Abdulla M., Athar M. Evidence that in situ generated reactive oxygen species act as a potent stage I tumor promoter in mouse skin. Biochem. Biophys. Res. Comm. 209:1995;698-705.
125. Giri U., Iqbal M., Athar M. Porphyrin-mediated photosensitization has a weak tumor promoting activity in mouse skin Possible role of in situ-generated reactive oxygen species. Carcinogenesis. 17:1996;2023-2028.
126. Stender I.M., Bech-Thomsen N., Poulsen T., Wulf H.C. Photodynamic therapy with topical delta-aminolevulinic acid delays UV photocarcinogenesis in hairless mice. Photochem. Photobiol. 66:1997;493-496.
127. Hayatsu H., Negishi T., Arimoto S., Hayatsu T. Porphyrins as potential inhibitors against exposure to carcinogens and mutagens. Mutat.Res. 290:1993;79-85.
128. Odin A.P. Antimutagenicity of the porphyrins and non-enzyme porphyrin containing proteins. Mutat. Res. 387:1997;55-68.
129. Ferguson L.R. Antimutagen as cancer chemopreventive agents in the diet. Mutat. Res. 307:1994;395-410.
130. Williams M., Krootjes B.B.H., Van Steveninck J., Van Der Zee J. The pro- and antioxidant properties of protoporphyrin IX. Biochim. Biophys. Acta. 1211:1994;310-316.
131. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antoxidant of possible physiological importance. Science. 235:1987;1043-1046.
132. Koningsberger J.C., Van Asbeck B.S., Van Hattum J., Wiegman L.J.J.M., Van Berge Henegouwen G.P., Marx J.J.M. The effect of porphyrins on cellular redox systems a study on the dark effect of porphyrins on phagocytes. Eur. J. Clin. Invest. 23:1993;716-723.
133. Imai, K.; Aimoto, T.; Sato, M.; Kimura, R. Antioxidative effect of several porphyrins on lipid peroxidation in rat liver homogenates. Chem. Pharm. Bull. (Tokyo) 38:258-260; 1990.
134. Imai K., Aimoto T., Sato M., Kimura R. Resistance of hepatic lysosomes, mitochondria and microsomes of protoporphyrin-administered rats to peroxidative damage. Biol. Pharm. 18:1995;913-916.
135. Day B.J., Fridovich I., Crapo J.D. Manganic porphyrins possess catalase activity and protect endothelial cells against hydrogen peroxide mediated injury. Arch. Biochem. Biophys. 347:1997;256-262.
136. Pasternack R.F., Banth A., Pasternack J.M., Johnson C.S. Catalysis of the disproportionation of superoxide by metalloporphyrins. J. Inorg. Biochem. 15:1981;261-267.
137. Day B.J., Crapo J.D. A metalloporphyrin superoxide dismutase mimetic protects against paraquat induced lung injury in-vivo. Toxicol. Appl. Pharmacol. 140:1996;94-100.
138. Peretz P., Solomon D., Weinraub D., Faraggi M. Chemical properties of water soluble porphyrins. 3. The reaction of superoxide with some small metalloporphyrins. Int. J. Radiat. Biol. 42:1982;449-456.
139. Faulkner K.M., Liochev S.I., Fridovich I. Stable Mn(III)porphyrins mimic superoxide dismutase in vitro and substitute for it in vivo. J. Biol. Chem. 269:1994;23471-23476.
140. Szabo C., Day B.J., Salzman A.L. Evaluation of the relative contribution of nitric oxide and peroxynitrite to the suppression of mitochondrial respiration in immunostimulated macrophages using a manganese mesoporphyrin superoxide dismutase mimetic and peroxynitrite scavenger. FEBS Lett. 381:1996;82-86.
141. Lee J., Hunt J.A., Groves J.T. Rapid decomposition of peroxynitrite by manganese porphyrin antioxidant redox couples. Bioorg. Med. Chem. Lett. 7:1997;2913-2918.
142. Day B.J., Batinic-Haberle I., Crapo J.D. Metalloporphyrins are potent inhibitors of lipid peroxidation. Free Radic. Biol. Med. 26:1999;730-736.
143. Wolf P., Rieger E., Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5 aminolevulinic acid an alternative treatment modality for solar keratoses superficial squamous cell carcinomas and basal cell carcinomas? J. Am. Acad. Dermatol. 28:1993;17-21.
144. Fink-Puches R., Soyer H.P., Hofer A., Karl H., Wolf P. Long term follow up and histological changes of superficial nonmelanoma skin cancers treated with topical d-aminolevulinic acid photodynamic therapy. Arch. Dermatol. 134:1998;821-826.
145. Calzavara-Pinton P.G., Szeimies R.-M., Ortel B., Zane C. Photodynamic therapy with systemic administration of photosensitizers in dermatology. J. Photochem. Photobiol. B Biol. 36:1996;225-231.
146. Messmann H., Mlokvy P., Buonaccorsi G., Davies C.L., MacRobert A.J., Bown S.G. Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. Br. J. Cancer. 72:1995;589-594.
147. Peng, Q.; Warloe, T.; Berg, K.; Moan, J.; Kongshaug, M.; Giercksky, K. E.; Nesland, J. M. 5-Aminolevulinic acid-based photodynamic therapy: Clinical research and future challenges. Cancer 79:2282-2308; 1997.
148. Fuchs J., Thiele J. The role of oxygen in cutaneous photodynamic therapy. Free Radic. Biol. Med. 24:1998;835-847.
149. Stewart F., Baas P., Star W. What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)? Radiother. Oncol. 48:1998;233-248.
150. Moan, J.; Berg, K.; Kvam, E. Effects of photodynamic treatment on DNA and DNA related cell functions. In: Kessel, D., ed. Photodynamic Therapy of Neoplastic Disease, Vol I. Boca Raton, FL: CRC Press, 1990:197-209.
151. Bengtsson N.O., Hardell L. Porphyrias, porphyrins and hepatocellular cancer. Br J Cancer. 54:1986;115-117.
152. Paraskevopoulos J.A. Management options for primary hepatocellular carcinoma. An overview. Acta. Oncologica. 33:1994;895-900.
153. Donaldson E.M., Donaldson A.D., Rimington C. Erythropoietic protoporphyria, a family study. Br. Med. J. 1:1967;659-663.
154. Lithner F., Wettenberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta. Med. Scand. 215:1984;271-274.
155. Kauppinen R., Mustajoki P. Acute hepatic porphyria and hepatocellular cancer. Br. J. Cancer. 57:1988;117-120.
156. Andant C., Puy H., Faivre J., Deybach J.C. Acute hepatic porphyrias and primary liver cancer. N. Engl. J. Med. 338:1998;1853-1854.
157. Weinberg A.G., Mize C.E., Morten H.G. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J. Pediatrics. 88:1976;433-438.
158. Sunderman F.W. Recent advances in metal carcinogenesis. Ann. Clin. Lab. Sci. 14:1984;93-122.
159. Kordak V. Frequence of occurrence of hepatocellular carcinoma in patients with porphyria cutanea tarda in long term follow up. Neoplasma. 19:1972;135-139.
160. Solis J.A., Betancor P., Campos R., Salamanca P., Marin I., Schuller A. Association of porphyria cutanea tarda and primary liver cancer. Report of ten cases. J. Dermatol. 9:1982;131-137.
161. Salata, H. H.; Corts, J. M.; Salamanca, R. E.; Oliva, H.; Kusak, E.; Carreno, V.; Hernandez Guio C. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency and occurrence of related factors. J Hepatol 1:477-482; 1985.
162. Bergmann J., Braun A. Incidence of hepatoma in porphyria cutanea tarda. Rev. Czech Med. 8:1962;290-315.
163. Siersema P.D., Kate T.F.J., Mulder P.G., Wilson J.H. Hepatocellular carcinoma in porphyria cutanea tarda frequency and factors related to its occurrence. Liver. 12:1992;56-61.
164. Lim H.W., Mascaro J.M. The porphyrias and hepatocellular carcinoma. Dermatol. Clin. 13:1995;135-142.
165. Nordman Y., Deybach J.C. Congenital erythropoietic porphyria. Semin. Dermatol. 5:1986;106-114.
166. Rorsman, H.; Harber, L. C. Cutaneous porphyrias. Acta. Dermatol. Venerol. (Stockh.) 100(Suppl.):1-131; 1982.
167. Todd D.J. Erythropoietic protoporphyria. Br. J. Dermatol. 131:1994;751-766.
168. Poh-Fitzpatrick M.B. Erythropoietic protoporphyria. Semin. Dermatol. 5:1986;99-105.
169. Harber, L. C.; Poh-Fitzpatrick, M. B.; Walther, R. R.; Grossman, M. E. Cutaneous aspects of the porphyrias. Acta. Dermato. Venereol. (Stockh.) 100(Suppl):9-15; 1982.
170. Baart de la Faille, H.; Bijlmer-Iest, J. C.; van Hattum J. Erythropoietic protoporphyria: Clinical aspects with emphasis on the skin. Curr. Probl. Dermatol. 20:123-134; 1991.
171. Wolf P., Fink-Puches R., Reimann-Weber A., Kerl H. Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. Dermatology. 194:1997;53-54.
172. Lever L.R., Farr P.M. Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. Br. J. Dermatol. 131:1994;215-219.
173. McKenna K.E., Patterson C.C., Handley J., McGinn S., Allen G. Cutaneous neoplasia following PUVA therapy for psoriasis. Br. J. Dermatol. 134:1996;639-642.
174. Maier H., Schemper M., Ortel B., Binder M., Tanew A., Honigsmann H. Skin tumors in photochemotherapy for psoriasis a single-center follow-up of 496 patients. Dermatology. 193:1996;185-191.
175. Stern R.S., Nichols K.T., Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N. Engl. J. Med. 336:1997;1041-1045.
176. Stern R.S., Lunder E.J. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch. Dermatol. 134:1998;1582-1585.